ISCO - International Stem Cell Corporation

Other OTC - Other OTC Delayed Price. Currency in USD
1.63
-0.01 (-0.61%)
At close: 3:56PM EST
Stock chart is not supported by your current browser
Previous Close1.64
Open1.63
Bid0.00 x 0
Ask0.00 x 0
Day's Range1.62 - 1.66
52 Week Range0.92 - 2.50
Volume11,052
Avg. Volume6,759
Market Cap9.832M
Beta0.32
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • International Stem Cell Corp. :ISCO-US: Earnings Analysis: Q3, 2017 By the Numbers : December 27, 2017
    Capital Cube21 days ago

    International Stem Cell Corp. :ISCO-US: Earnings Analysis: Q3, 2017 By the Numbers : December 27, 2017

    Categories: Yahoo FinanceGet free summary analysis International Stem Cell Corp. reports financial results for the quarter ended September 30, 2017. We analyze the earnings along side the following peers of International Stem Cell Corp. – Keryx Biopharmaceuticals, Inc., Acer Therapeutics Inc., Anthera Pharmaceuticals, Inc., Chimerix, Inc. and Vericel Corporation (KERX-US, ACER-US, ANTH-US, CMRX-US and VCEL-US) that have ... Read more (Read more...)

  • GuruFocus.comlast month

    International Stem Cell Corp (ISCO) CEO Andrey Semechkin Bought $3.3 million of Shares

    CEO of International Stem Cell Corp (ISCO) Andrey Semechkin bought 1,860,810 shares of ISCO on 12/07/2017 at an average price of $1.75 a share.

  • International Stem Cell Corp. :ISCO-US: Earnings Analysis: Q2, 2017 By the Numbers : September 18, 2017
    Capital Cube4 months ago

    International Stem Cell Corp. :ISCO-US: Earnings Analysis: Q2, 2017 By the Numbers : September 18, 2017

    Categories: Yahoo FinanceGet free summary analysis International Stem Cell Corp. reports financial results for the quarter ended June 30, 2017. We analyze the earnings along side the following peers of International Stem Cell Corp. – Keryx Biopharmaceuticals, Inc., Opexa Therapeutics, Inc., Celgene Corporation, Anthera Pharmaceuticals, Inc., Chimerix, Inc. and Vericel Corporation (KERX-US, OPXA-US, CELG-US, ANTH-US, CMRX-US and ... Read more (Read more...)

  • International Stem Cell Corp. :ISCO-US: Earnings Analysis: Q1, 2017 By the Numbers : June 13, 2017
    Capital Cube7 months ago

    International Stem Cell Corp. :ISCO-US: Earnings Analysis: Q1, 2017 By the Numbers : June 13, 2017

    Categories: Yahoo FinanceGet free summary analysis International Stem Cell Corp. reports financial results for the quarter ended March 31, 2017. We analyze the earnings along side the following peers of International Stem Cell Corp. – Keryx Biopharmaceuticals, Inc., Opexa Therapeutics, Inc., Celgene Corporation, Anthera Pharmaceuticals, Inc., Chimerix, Inc. and Vericel Corporation (KERX-US, OPXA-US, CELG-US, ANTH-US, CMRX-US and ... Read more (Read more...)

  • International Stem Cell Corp. :ISCO-US: Earnings Analysis: Q4, 2016 By the Numbers : April 5, 2017
    Capital Cube9 months ago

    International Stem Cell Corp. :ISCO-US: Earnings Analysis: Q4, 2016 By the Numbers : April 5, 2017

    Categories: Yahoo FinanceGet free summary analysis International Stem Cell Corp. reports financial results for the quarter ended December 31, 2016. Highlights Summary numbers: Revenues of USD 1.69 million, Net Earnings of USD 2.16 million. Gross margins widened from 70.53% to 71.18% compared to the same period last year, operating (EBITDA) margins now -62.96% from -42.97%. Change in ... Read more (Read more...)